Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MDKP 67b

X
Drug Profile

MDKP 67b

Alternative Names: DIM-107; DM 107; hK2 inhibitors; MDPK-67-b; RIK-7

Latest Information Update: 18 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Med Discovery
  • Developer Dermadis; Med Discovery; University of Zurich
  • Class Antineoplastics; Recombinant proteins; Skin disorder therapies
  • Mechanism of Action Peptide hydrolase inhibitors; Serine endopeptidase inhibitors; Tissue kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Netherton Syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer
  • No development reported Atopic dermatitis; Netherton Syndrome; Neutropenia; Psoriasis

Most Recent Events

  • 28 Apr 2021 No recent reports of development identified for phase-I development in Prostate-cancer(In volunteers) in Switzerland (Parenteral, Infusion)
  • 23 Sep 2010 Preclinical trials in Netherton Syndrome in France (Topical)
  • 23 Mar 2010 Preclinical trials in Atopic dermatitis in France (Topical)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top